
Clayton Vickers
Antitrust Reporter at MLex Market Insight
Antitrust Reporter at MLex
Articles
-
6 days ago |
mlex.com | Clayton Vickers
By Clayton Vickers ( April 18, 2025, 21:56 GMT | Insight) -- X Corp. lost its bid to dismiss Bright Data’s US monopolization counterclaims today, with a California federal judge accepting arguments that the social media platform unlawfully changed its own rules to force out data scrapers and punish entities who bought from them.X Corp.
-
1 week ago |
mlex.com | Clayton Vickers
By Clayton Vickers ( April 15, 2025, 20:43 GMT | Insight) -- Google told a US judge its proposed remedies address much more than the specific conduct the court identified as anticompetitive, and that the US Department of Justice's proposals would carry devastating consequences.Google told a US judge its proposed remedies address much more than the specific conduct the court identified as anticompetitive, and that the US Department of Justice's proposals would carry devastating consequences....
-
1 week ago |
mlex.com | Clayton Vickers
By Clayton Vickers ( April 14, 2025, 23:05 GMT | Insight) -- Counsel for student athlete Robert Beasley told a US judge today that student athletes face a “Hobbesian choice” over the NCAA’s second transfer rule, and that the court should issue a temporary restraining order to let Beasley negotiate a potential transfer.Counsel for student athlete Robert Beasley told a US judge today that student athletes face a “Hobbesian choice” over the NCAA’s second transfer rule, and that the court should...
-
1 week ago |
mlex.com | Clayton Vickers
By Clayton Vickers ( April 14, 2025, 21:32 GMT | Insight) -- Sandoz has filed a US antitrust complaint accusing Amgen and subsidiary Immunex of unlawfully extending and entrenching a monopoly over the blockbuster drug Enbrel by blocking biosimilar competitors through patent litigation.Sandoz has filed a US antitrust complaint accusing Amgen and subsidiary Immunex of unlawfully extending and entrenching a monopoly over the blockbuster drug Enbrel by blocking biosimilar competitors through...
-
2 weeks ago |
mlex.com | Clayton Vickers
By Clayton Vickers ( April 9, 2025, 21:29 GMT | Insight) -- Celgene, Anthony Insogna and Jerome Zeldis have been granted dismissal of Blue Cross Blue Shield’s US antitrust claims that Celgene obtained patents on the drug Pomalyst fraudulently to monopolize the relevant market.Celgene, Anthony Insogna and Jerome Zeldis last week were granted dismissal of Blue Cross Blue Shield’s US antitrust claims that Celgene obtained patents on the drug Pomalyst fraudulently to monopolize the relevant...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →